Análisis de ratios de rentabilidad
Datos trimestrales
Los índices de rentabilidad miden la capacidad de la empresa para generar ventas rentables a partir de sus recursos (activos).
Índices de rentabilidad (resumen)
AbbVie Inc., ratios de rentabilidad (datos trimestrales)
Fuente: AbbVie Inc. (NYSE:ABBV) | Analysis of profitability ratios (Q) (www.stock-analysis-on.net)
Coeficiente de rentabilidad | Descripción | La compañia |
---|---|---|
Ratio de margen de beneficio bruto | El índice de margen de beneficio bruto indica el porcentaje de ingresos disponibles para cubrir gastos operativos y otros gastos. | El índice de margen de beneficio bruto de AbbVie Inc. se deterioró del primer trimestre de 2020 al segundo trimestre de 2020 y del segundo trimestre de 2020 al tercer trimestre de 2020. |
Ratio de margen de beneficio operativo | Un índice de rentabilidad calculado como el ingreso operativo dividido por los ingresos. | El índice de margen de beneficio operativo de AbbVie Inc. se deterioró desde el primer trimestre de 2020 hasta el segundo trimestre de 2020 y desde el segundo trimestre de 2020 hasta el tercer trimestre de 2020. |
Ratio de margen de beneficio neto | Un indicador de rentabilidad, calculado como el ingreso neto dividido por los ingresos. | El índice de margen de beneficio neto de AbbVie Inc. se deterioró del primer trimestre de 2020 al segundo trimestre de 2020 y del segundo trimestre de 2020 al tercer trimestre de 2020. |
Coeficiente de rentabilidad | Descripción | La compañia |
---|---|---|
ROA | Un índice de rentabilidad calculado como el ingreso neto dividido entre los activos totales. | El ROA de AbbVie Inc. se deterioró desde el primer trimestre de 2020 hasta el segundo trimestre de 2020, pero luego mejoró ligeramente desde el segundo trimestre de 2020 hasta el tercer trimestre de 2020. |
Ratio de margen de beneficio bruto
AbbVie Inc., margen de beneficio bruto, cálculo (datos trimestrales)
30 sept. 2020 | 30 jun. 2020 | 31 mar. 2020 | 31 dic. 2019 | 30 sept. 2019 | 30 jun. 2019 | 31 mar. 2019 | 31 dic. 2018 | 30 sept. 2018 | 30 jun. 2018 | 31 mar. 2018 | 31 dic. 2017 | 30 sept. 2017 | 30 jun. 2017 | 31 mar. 2017 | 31 dic. 2016 | 30 sept. 2016 | 30 jun. 2016 | 31 mar. 2016 | 31 dic. 2015 | 30 sept. 2015 | 30 jun. 2015 | 31 mar. 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Datos financieros seleccionados (US $ en millones) | ||||||||||||||||||||||||||||||
Margen bruto | 7,852 | 6,714 | 6,677 | 6,698 | 6,559 | 6,436 | 6,134 | 6,283 | 6,401 | 6,344 | 6,007 | 5,459 | 5,379 | 5,416 | 4,922 | 5,241 | 4,928 | 5,047 | 4,589 | 4,925 | 4,777 | 4,559 | 4,098 | |||||||
Los ingresos netos | 12,902 | 10,425 | 8,619 | 8,704 | 8,479 | 8,255 | 7,828 | 8,305 | 8,236 | 8,278 | 7,934 | 7,739 | 6,995 | 6,944 | 6,538 | 6,796 | 6,432 | 6,452 | 5,958 | 6,400 | 5,944 | 5,475 | 5,040 | |||||||
Coeficiente de rentabilidad | ||||||||||||||||||||||||||||||
Ratio de margen de beneficio bruto1 | 68.74% | 73.56% | 77.43% | 77.64% | 77.32% | 77.41% | 77.07% | 76.44% | 75.22% | 74.93% | 75.18% | 75.05% | 76.85% | 76.78% | 76.81% | 77.25% | 77.21% | 78.12% | 79.28% | 80.31% | — | — | — | |||||||
Puntos de referencia | ||||||||||||||||||||||||||||||
Ratio de margen de beneficio bruto, competidores2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 50.18% | 50.97% | 52.13% | 52.46% | 52.39% | 52.17% | 51.57% | 51.32% | 50.57% | 50.38% | 49.39% | 47.75% | 48.59% | 49.21% | 51.32% | 54.09% | 54.17% | 53.99% | 53.93% | 54.19% | — | — | — | |||||||
Amgen Inc. | 75.55% | 77.15% | 78.90% | 80.38% | 81.19% | 81.23% | 81.26% | 81.80% | 81.61% | 81.78% | 81.69% | 81.33% | 81.37% | 81.26% | 81.05% | 80.99% | 80.68% | 80.64% | 80.23% | 79.82% | — | — | — | |||||||
Bristol-Myers Squibb Co. | 71.18% | 69.47% | 68.02% | 69.10% | 69.90% | 70.10% | 70.86% | 70.98% | 70.37% | 70.12% | 69.62% | 70.80% | 71.92% | 72.78% | 74.19% | 74.54% | 75.56% | 75.55% | 75.67% | 76.39% | — | — | — | |||||||
Eli Lilly & Co. | 78.26% | 78.67% | 79.22% | 78.85% | 77.78% | 76.67% | 74.96% | 73.81% | 73.39% | 72.92% | 72.95% | 73.46% | 73.69% | 73.89% | 73.78% | 73.35% | 73.23% | 73.72% | 74.39% | 74.76% | — | — | — | |||||||
Gilead Sciences Inc. | 78.72% | 78.25% | 79.06% | 78.86% | 79.27% | 78.98% | 78.02% | 77.61% | 79.21% | 80.31% | 81.82% | 82.97% | 84.51% | 84.71% | 85.95% | 85.77% | 86.36% | 86.91% | 86.69% | 87.54% | — | — | — | |||||||
Illumina Inc. | 69.02% | 70.34% | 70.36% | 69.63% | 69.24% | 68.84% | 69.06% | 69.01% | 69.44% | 68.85% | 67.98% | 66.35% | 65.68% | 66.26% | 67.53% | 69.48% | 69.91% | 69.96% | 69.74% | 69.80% | — | — | — | |||||||
Johnson & Johnson | 65.68% | 65.66% | 66.15% | 66.42% | 66.49% | 66.67% | 66.80% | 66.79% | 66.36% | 65.69% | 66.22% | 66.84% | 68.20% | 69.35% | 69.88% | 69.84% | 69.52% | 69.58% | 69.25% | 69.27% | — | — | — | |||||||
Merck & Co. Inc. | 71.23% | 70.06% | 70.11% | 69.87% | 70.13% | 69.89% | 68.94% | 68.06% | 67.35% | 67.81% | 68.22% | 68.16% | 68.09% | 67.92% | 66.61% | 65.10% | 63.89% | 62.58% | 62.07% | 62.19% | — | — | — | |||||||
Pfizer Inc. | 79.86% | 79.94% | 79.94% | 80.25% | 79.85% | 79.91% | 79.36% | 79.03% | 78.58% | 78.24% | 78.48% | 78.61% | 78.66% | 78.15% | 77.28% | 76.66% | 76.48% | 77.71% | 79.09% | 80.25% | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 87.98% | 88.21% | 89.72% | 90.05% | 91.14% | 92.27% | 92.79% | 93.53% | 93.36% | 93.28% | 92.95% | 93.24% | 93.37% | 94.16% | 94.53% | 93.83% | 92.90% | 91.38% | 90.52% | 90.43% | — | — | — | |||||||
Vertex Pharmaceuticals Inc. | 88.01% | 87.71% | 87.24% | 86.84% | 86.60% | 86.56% | 86.74% | 86.56% | 86.88% | 87.31% | 87.59% | 88.95% | 89.04% | 89.08% | 89.76% | 87.64% | 87.16% | 87.72% | 87.39% | 87.94% | — | — | — | |||||||
Zoetis Inc. | 69.64% | 69.73% | 69.51% | 68.18% | 67.38% | 66.92% | 66.49% | 67.19% | 68.12% | 68.04% | 67.31% | 66.55% | 65.14% | 64.91% | 65.30% | 65.92% | 65.32% | 64.90% | 64.08% | 63.53% | — | — | — |
Fuente: AbbVie Inc. (NYSE:ABBV) | Analysis of profitability ratios (Q) (www.stock-analysis-on.net)
1 Q3 2020 cálculo
Ratio de margen de beneficio bruto = 100
× (Margen brutoQ3 2020
+ Margen brutoQ2 2020
+ Margen brutoQ1 2020
+ Margen brutoQ4 2019)
÷ (Los ingresos netosQ3 2020
+ Los ingresos netosQ2 2020
+ Los ingresos netosQ1 2020
+ Los ingresos netosQ4 2019)
= 100 × (7,852 + 6,714 + 6,677 + 6,698)
÷ (12,902 + 10,425 + 8,619 + 8,704)
= 68.74%
2 Haga clic en el nombre del competidor para ver los cálculos.
Coeficiente de rentabilidad | Descripción | La compañia |
---|---|---|
Ratio de margen de beneficio bruto | El índice de margen de beneficio bruto indica el porcentaje de ingresos disponibles para cubrir gastos operativos y otros gastos. | El índice de margen de beneficio bruto de AbbVie Inc. se deterioró del primer trimestre de 2020 al segundo trimestre de 2020 y del segundo trimestre de 2020 al tercer trimestre de 2020. |
Ratio de margen de beneficio operativo
AbbVie Inc., ratio de margen de beneficio operativo, cálculo (datos trimestrales)
30 sept. 2020 | 30 jun. 2020 | 31 mar. 2020 | 31 dic. 2019 | 30 sept. 2019 | 30 jun. 2019 | 31 mar. 2019 | 31 dic. 2018 | 30 sept. 2018 | 30 jun. 2018 | 31 mar. 2018 | 31 dic. 2017 | 30 sept. 2017 | 30 jun. 2017 | 31 mar. 2017 | 31 dic. 2016 | 30 sept. 2016 | 30 jun. 2016 | 31 mar. 2016 | 31 dic. 2015 | 30 sept. 2015 | 30 jun. 2015 | 31 mar. 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Datos financieros seleccionados (US $ en millones) | ||||||||||||||||||||||||||||||
Ganancias operativas | 3,255 | 752 | 3,603 | 3,956 | 2,617 | 3,400 | 3,010 | (2,441) | 3,159 | 2,762 | 2,903 | 1,794 | 2,705 | 2,674 | 2,419 | 2,358 | 2,361 | 2,387 | 2,278 | 2,113 | 1,885 | 1,852 | 1,687 | |||||||
Los ingresos netos | 12,902 | 10,425 | 8,619 | 8,704 | 8,479 | 8,255 | 7,828 | 8,305 | 8,236 | 8,278 | 7,934 | 7,739 | 6,995 | 6,944 | 6,538 | 6,796 | 6,432 | 6,452 | 5,958 | 6,400 | 5,944 | 5,475 | 5,040 | |||||||
Coeficiente de rentabilidad | ||||||||||||||||||||||||||||||
Ratio de margen de beneficio operativo1 | 28.45% | 30.17% | 39.86% | 39.03% | 20.04% | 21.85% | 19.88% | 19.49% | 32.99% | 32.84% | 34.03% | 33.99% | 37.24% | 36.74% | 36.33% | 36.60% | 36.21% | 35.00% | 34.18% | 32.97% | — | — | — | |||||||
Puntos de referencia | ||||||||||||||||||||||||||||||
Ratio de margen de beneficio operativo, competidores2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 13.39% | 12.78% | 14.18% | 14.21% | 13.74% | 13.27% | 12.31% | 11.94% | 10.45% | 10.11% | 8.92% | 6.30% | 7.89% | 8.77% | 11.03% | 15.27% | 14.74% | 13.95% | 13.64% | 14.05% | — | — | — | |||||||
Amgen Inc. | 38.59% | 39.76% | 41.89% | 43.57% | 44.83% | 44.05% | 44.53% | 45.55% | 45.82% | 46.46% | 46.07% | 45.76% | 46.66% | 46.93% | 45.68% | 44.74% | 43.33% | 42.46% | 41.53% | 40.44% | — | — | — | |||||||
Bristol-Myers Squibb Co. | 9.27% | 11.67% | 16.30% | 22.62% | 28.63% | 28.59% | 23.43% | 22.69% | 18.64% | 15.93% | 17.50% | 17.39% | 19.71% | 21.73% | 24.06% | 23.83% | 19.21% | 16.34% | 11.09% | 11.41% | — | — | — | |||||||
Eli Lilly & Co. | 23.55% | 24.48% | 25.64% | 22.29% | 20.00% | 19.48% | 12.50% | 15.15% | 12.34% | 9.11% | 14.88% | 9.38% | 12.43% | 14.23% | 12.92% | 16.30% | 14.31% | 14.56% | 14.27% | 13.47% | — | — | — | |||||||
Gilead Sciences Inc. | 11.01% | -4.40% | 19.89% | 19.38% | 19.71% | 38.44% | 37.87% | 37.83% | 42.81% | 46.25% | 51.51% | 55.04% | 58.72% | 58.71% | 58.46% | 58.87% | 61.67% | 63.83% | 66.22% | 69.03% | — | — | — | |||||||
Illumina Inc. | 22.08% | 25.69% | 27.28% | 27.80% | 26.42% | 24.88% | 25.58% | 26.49% | 28.25% | 27.58% | 26.29% | 22.02% | 20.01% | 20.06% | 21.35% | 24.48% | 24.80% | 24.55% | 24.77% | 27.61% | — | — | — | |||||||
Johnson & Johnson | 24.30% | 24.64% | 25.62% | 24.15% | 24.15% | 22.63% | 22.69% | 24.27% | 22.59% | 23.05% | 23.63% | 24.07% | 27.02% | 28.55% | 28.83% | 28.72% | 26.37% | 25.66% | 25.00% | 25.05% | — | — | — | |||||||
Merck & Co. Inc. | 26.87% | 25.40% | 25.49% | 24.77% | 25.56% | 26.73% | 24.38% | 19.62% | 17.84% | 12.28% | 13.57% | 16.28% | 9.92% | 16.85% | 14.45% | 13.51% | 19.60% | 18.10% | 18.19% | 17.54% | — | — | — | |||||||
Pfizer Inc. | 24.77% | 23.75% | 25.38% | 25.46% | 26.30% | 27.50% | 26.86% | 26.10% | 26.18% | 26.00% | 25.86% | 25.92% | 24.69% | 23.57% | 22.94% | 22.73% | 22.96% | 24.02% | 24.86% | 24.20% | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 37.43% | 34.64% | 30.45% | 28.10% | 29.55% | 29.58% | 35.41% | 37.77% | 37.00% | 36.89% | 36.54% | 35.41% | 34.22% | 32.29% | 28.76% | 27.38% | 25.67% | 26.77% | 29.26% | 30.51% | — | — | — | |||||||
Vertex Pharmaceuticals Inc. | 44.43% | 38.67% | 34.05% | 28.77% | 21.38% | 25.48% | 23.98% | 20.84% | 22.38% | 3.87% | -0.77% | 4.95% | 1.62% | 16.16% | 14.62% | 0.58% | -5.02% | -8.65% | -23.94% | -45.23% | — | — | — | |||||||
Zoetis Inc. | 33.87% | 33.36% | 32.72% | 31.42% | 31.01% | 29.80% | 30.05% | 31.12% | 33.00% | 33.86% | 33.02% | 32.15% | 29.43% | 28.34% | 28.55% | 28.48% | 26.22% | 24.91% | 17.35% | 15.74% | — | — | — |
Fuente: AbbVie Inc. (NYSE:ABBV) | Analysis of profitability ratios (Q) (www.stock-analysis-on.net)
1 Q3 2020 cálculo
Ratio de margen de beneficio operativo = 100
× (Ganancias operativasQ3 2020
+ Ganancias operativasQ2 2020
+ Ganancias operativasQ1 2020
+ Ganancias operativasQ4 2019)
÷ (Los ingresos netosQ3 2020
+ Los ingresos netosQ2 2020
+ Los ingresos netosQ1 2020
+ Los ingresos netosQ4 2019)
= 100 × (3,255 + 752 + 3,603 + 3,956)
÷ (12,902 + 10,425 + 8,619 + 8,704)
= 28.45%
2 Haga clic en el nombre del competidor para ver los cálculos.
Coeficiente de rentabilidad | Descripción | La compañia |
---|---|---|
Ratio de margen de beneficio operativo | Un índice de rentabilidad calculado como el ingreso operativo dividido por los ingresos. | El índice de margen de beneficio operativo de AbbVie Inc. se deterioró del primer trimestre de 2020 al segundo trimestre de 2020 y del segundo trimestre de 2020 al tercer trimestre de 2020. |
Ratio de margen de beneficio neto
AbbVie Inc., margen de beneficio neto, cálculo (datos trimestrales)
30 sept. 2020 | 30 jun. 2020 | 31 mar. 2020 | 31 dic. 2019 | 30 sept. 2019 | 30 jun. 2019 | 31 mar. 2019 | 31 dic. 2018 | 30 sept. 2018 | 30 jun. 2018 | 31 mar. 2018 | 31 dic. 2017 | 30 sept. 2017 | 30 jun. 2017 | 31 mar. 2017 | 31 dic. 2016 | 30 sept. 2016 | 30 jun. 2016 | 31 mar. 2016 | 31 dic. 2015 | 30 sept. 2015 | 30 jun. 2015 | 31 mar. 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Datos financieros seleccionados (US $ en millones) | ||||||||||||||||||||||||||||||
Ganancias (pérdidas) netas atribuibles a AbbVie Inc. | 2,308 | (738) | 3,010 | 2,801 | 1,884 | 741 | 2,456 | (1,826) | 2,747 | 1,983 | 2,783 | 52 | 1,631 | 1,915 | 1,711 | 1,391 | 1,598 | 1,610 | 1,354 | 1,517 | 1,239 | 1,366 | 1,022 | |||||||
Los ingresos netos | 12,902 | 10,425 | 8,619 | 8,704 | 8,479 | 8,255 | 7,828 | 8,305 | 8,236 | 8,278 | 7,934 | 7,739 | 6,995 | 6,944 | 6,538 | 6,796 | 6,432 | 6,452 | 5,958 | 6,400 | 5,944 | 5,475 | 5,040 | |||||||
Coeficiente de rentabilidad | ||||||||||||||||||||||||||||||
Ratio de margen de beneficio neto1 | 18.16% | 19.20% | 24.77% | 23.69% | 9.90% | 12.62% | 16.42% | 17.36% | 23.50% | 20.84% | 21.55% | 18.82% | 24.38% | 24.77% | 24.07% | 23.22% | 24.08% | 23.11% | 23.03% | 22.50% | — | — | — | |||||||
Puntos de referencia | ||||||||||||||||||||||||||||||
Ratio de margen de beneficio neto, competidores2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 10.50% | 9.89% | 11.15% | 11.56% | 10.50% | 9.36% | 8.53% | 7.74% | 2.91% | 3.13% | 1.67% | 1.74% | 8.37% | 4.96% | 6.74% | 6.71% | 6.61% | 11.08% | 12.00% | 21.68% | — | — | — | |||||||
Amgen Inc. | 30.91% | 31.53% | 33.64% | 35.32% | 36.14% | 35.57% | 35.93% | 37.25% | 9.96% | 10.72% | 10.11% | 9.08% | 37.36% | 37.24% | 36.12% | 35.27% | 35.19% | 34.48% | 33.86% | 33.13% | — | — | — | |||||||
Bristol-Myers Squibb Co. | -0.11% | -1.61% | 3.08% | 13.15% | 23.39% | 26.00% | 22.09% | 21.81% | 6.50% | 1.74% | 4.37% | 4.85% | 20.56% | 22.66% | 24.22% | 22.94% | 18.22% | 16.29% | 9.31% | 9.45% | — | — | — | |||||||
Eli Lilly & Co. | 24.01% | 24.48% | 23.97% | 37.27% | 35.10% | 33.76% | 26.12% | 13.16% | 1.85% | -0.60% | 4.82% | -0.89% | 9.90% | 11.12% | 10.13% | 12.90% | 11.73% | 11.97% | 11.49% | 12.07% | — | — | — | |||||||
Gilead Sciences Inc. | 5.56% | -1.18% | 22.17% | 24.35% | 12.24% | 27.14% | 26.93% | 25.16% | 7.27% | 9.69% | 14.26% | 18.03% | 42.90% | 43.55% | 44.11% | 45.07% | 48.40% | 51.16% | 53.48% | 56.32% | — | — | — | |||||||
Illumina Inc. | 19.70% | 20.68% | 26.49% | 28.28% | 28.13% | 27.55% | 25.05% | 24.78% | 21.09% | 20.88% | 19.31% | 26.38% | 30.14% | 30.07% | 30.52% | 19.29% | 18.70% | 18.70% | 18.40% | 20.79% | — | — | — | |||||||
Johnson & Johnson | 21.01% | 18.86% | 20.75% | 18.42% | 17.32% | 20.08% | 17.99% | 18.75% | 1.89% | 1.70% | 1.58% | 1.70% | 21.28% | 22.52% | 22.87% | 23.01% | 22.27% | 21.20% | 22.15% | 21.99% | — | — | — | |||||||
Merck & Co. Inc. | 24.33% | 22.20% | 21.10% | 21.01% | 20.26% | 21.10% | 19.50% | 14.71% | 8.02% | 3.25% | 3.88% | 5.97% | 7.15% | 12.71% | 10.88% | 9.85% | 13.76% | 13.01% | 11.72% | 11.25% | — | — | — | |||||||
Pfizer Inc. | 17.85% | 28.80% | 31.17% | 31.45% | 30.57% | 23.58% | 21.31% | 20.79% | 44.63% | 42.35% | 41.29% | 40.55% | 18.69% | 15.90% | 13.88% | 13.66% | 11.77% | 13.47% | 14.95% | 14.25% | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 38.28% | 37.30% | 28.56% | 26.91% | 28.13% | 28.59% | 35.12% | 36.42% | 28.24% | 25.65% | 23.54% | 20.41% | 23.17% | 22.05% | 19.34% | 18.42% | 16.85% | 15.98% | 16.72% | 15.50% | — | — | — | |||||||
Vertex Pharmaceuticals Inc. | 44.91% | 38.51% | 31.35% | 28.27% | 59.23% | 64.13% | 66.01% | 68.80% | 22.87% | 15.84% | 9.36% | 10.59% | 8.53% | 12.19% | 8.78% | -6.58% | -13.17% | -17.66% | -30.91% | -53.89% | — | — | — | |||||||
Zoetis Inc. | 25.42% | 25.50% | 25.41% | 23.96% | 23.76% | 22.74% | 23.47% | 24.52% | 20.35% | 19.95% | 17.97% | 16.28% | 18.29% | 17.50% | 17.25% | 16.80% | 14.10% | 13.15% | 7.83% | 7.11% | — | — | — |
Fuente: AbbVie Inc. (NYSE:ABBV) | Analysis of profitability ratios (Q) (www.stock-analysis-on.net)
1 Q3 2020 cálculo
Ratio de margen de beneficio neto = 100
× (Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q3 2020
+ Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q2 2020
+ Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q1 2020
+ Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q4 2019)
÷ (Los ingresos netosQ3 2020
+ Los ingresos netosQ2 2020
+ Los ingresos netosQ1 2020
+ Los ingresos netosQ4 2019)
= 100 × (2,308 + -738 + 3,010 + 2,801)
÷ (12,902 + 10,425 + 8,619 + 8,704)
= 18.16%
2 Haga clic en el nombre del competidor para ver los cálculos.
Coeficiente de rentabilidad | Descripción | La compañia |
---|---|---|
Ratio de margen de beneficio neto | Un indicador de rentabilidad, calculado como el ingreso neto dividido por los ingresos. | El índice de margen de beneficio neto de AbbVie Inc. se deterioró desde el primer trimestre de 2020 hasta el segundo trimestre de 2020 y desde el segundo trimestre de 2020 hasta el tercer trimestre de 2020. |
Retorno sobre el capital contable (ROE)
AbbVie Inc., ROE, cálculo (datos trimestrales)
30 sept. 2020 | 30 jun. 2020 | 31 mar. 2020 | 31 dic. 2019 | 30 sept. 2019 | 30 jun. 2019 | 31 mar. 2019 | 31 dic. 2018 | 30 sept. 2018 | 30 jun. 2018 | 31 mar. 2018 | 31 dic. 2017 | 30 sept. 2017 | 30 jun. 2017 | 31 mar. 2017 | 31 dic. 2016 | 30 sept. 2016 | 30 jun. 2016 | 31 mar. 2016 | 31 dic. 2015 | 30 sept. 2015 | 30 jun. 2015 | 31 mar. 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Datos financieros seleccionados (US $ en millones) | ||||||||||||||||||||||||||||||
Ganancias (pérdidas) netas atribuibles a AbbVie Inc. | 2,308 | (738) | 3,010 | 2,801 | 1,884 | 741 | 2,456 | (1,826) | 2,747 | 1,983 | 2,783 | 52 | 1,631 | 1,915 | 1,711 | 1,391 | 1,598 | 1,610 | 1,354 | 1,517 | 1,239 | 1,366 | 1,022 | |||||||
Capital contable (déficit) | 15,270 | 14,708 | (7,415) | (8,172) | (8,226) | (8,566) | (7,826) | (8,446) | (2,921) | (3,375) | 3,553 | 5,097 | 6,687 | 6,009 | 4,998 | 4,636 | 6,469 | 5,640 | 4,643 | 3,945 | 4,863 | 5,504 | 1,377 | |||||||
Coeficiente de rentabilidad | ||||||||||||||||||||||||||||||
ROE1 | 48.34% | 47.30% | — | — | — | — | — | — | — | — | 179.59% | 104.16% | 99.42% | 110.08% | 126.25% | 128.41% | 93.97% | 101.42% | 117.94% | 130.39% | — | — | — | |||||||
Puntos de referencia | ||||||||||||||||||||||||||||||
ROE, competidores2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 10.78% | 10.17% | 11.84% | 11.86% | 10.35% | 9.14% | 8.48% | 7.76% | 2.89% | 3.03% | 1.52% | 1.54% | 6.57% | 3.71% | 4.79% | 6.82% | 6.59% | 11.02% | 11.81% | 20.85% | — | — | — | |||||||
Amgen Inc. | 67.09% | 68.48% | 80.92% | 81.07% | 73.83% | 73.73% | 74.55% | 67.15% | 15.35% | 15.86% | 14.21% | 7.84% | 25.37% | 25.77% | 25.76% | 25.85% | 24.65% | 24.67% | 25.16% | 24.71% | — | — | — | |||||||
Bristol-Myers Squibb Co. | -0.09% | -1.15% | 1.91% | 6.66% | 32.04% | 38.65% | 33.80% | 35.07% | 10.50% | 3.05% | 7.18% | 8.58% | 28.61% | 31.20% | 33.55% | 27.55% | 21.56% | 19.24% | 10.94% | 10.97% | — | — | — | |||||||
Eli Lilly & Co. | 115.45% | 137.26% | 179.72% | 319.09% | 234.97% | 282.08% | 252.24% | 32.88% | 3.44% | -1.24% | 7.74% | -1.76% | 14.94% | 17.35% | 15.58% | 19.54% | 15.68% | 16.85% | 15.45% | 16.53% | — | — | — | |||||||
Gilead Sciences Inc. | 7.27% | -1.43% | 22.49% | 23.91% | 13.07% | 26.33% | 26.84% | 25.51% | 6.94% | 10.19% | 16.82% | 22.64% | 46.69% | 53.86% | 61.82% | 71.48% | 89.38% | 105.21% | 129.43% | 97.70% | — | — | — | |||||||
Illumina Inc. | 13.57% | 15.19% | 20.32% | 21.72% | 21.92% | 21.65% | 21.36% | 21.98% | 19.53% | 19.90% | 18.85% | 26.41% | 27.38% | 27.54% | 29.01% | 21.06% | 19.79% | 21.05% | 20.82% | 24.97% | — | — | — | |||||||
Johnson & Johnson | 26.35% | 24.11% | 28.01% | 25.42% | 24.31% | 26.87% | 24.90% | 25.60% | 2.39% | 2.18% | 1.97% | 2.16% | 21.39% | 22.71% | 23.46% | 23.49% | 21.91% | 20.73% | 21.40% | 21.66% | — | — | — | |||||||
Merck & Co. Inc. | 39.47% | 37.91% | 38.72% | 37.99% | 34.70% | 33.88% | 30.50% | 23.30% | 10.32% | 4.12% | 4.69% | 6.97% | 7.44% | 12.89% | 10.91% | 9.78% | 12.55% | 11.84% | 10.53% | 9.94% | — | — | — | |||||||
Pfizer Inc. | 13.31% | 22.02% | 24.28% | 25.77% | 24.91% | 21.24% | 19.52% | 17.59% | 33.40% | 32.31% | 29.72% | 29.88% | 16.14% | 14.26% | 12.49% | 12.12% | 9.90% | 11.22% | 12.09% | 10.75% | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 31.17% | 32.94% | 18.79% | 19.08% | 20.41% | 21.21% | 25.70% | 27.91% | 22.85% | 22.14% | 21.74% | 19.51% | 21.12% | 20.91% | 19.79% | 20.13% | 17.75% | 18.23% | 19.69% | 17.40% | — | — | — | |||||||
Vertex Pharmaceuticals Inc. | 33.08% | 27.67% | 23.38% | 19.34% | 40.81% | 43.70% | 45.63% | 47.28% | 22.27% | 15.46% | 9.41% | 12.99% | 10.93% | 15.55% | 11.82% | -9.69% | -21.41% | -28.03% | -41.73% | -59.19% | — | — | — | |||||||
Zoetis Inc. | 46.17% | 54.23% | 58.52% | 55.39% | 54.56% | 57.03% | 59.91% | 65.35% | 54.96% | 56.60% | 49.90% | 48.81% | 47.11% | 51.20% | 53.14% | 55.21% | 43.47% | 47.09% | 32.45% | 31.74% | — | — | — |
Fuente: AbbVie Inc. (NYSE:ABBV) | Analysis of profitability ratios (Q) (www.stock-analysis-on.net)
1 Q3 2020 cálculo
ROE = 100
× (Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q3 2020
+ Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q2 2020
+ Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q1 2020
+ Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q4 2019)
÷ Capital contable (déficit)
= 100 × (2,308 + -738 + 3,010 + 2,801)
÷ 15,270 = 48.34%
2 Haga clic en el nombre del competidor para ver los cálculos.
Ratio de retorno sobre activos (ROA)
AbbVie Inc., ROA, cálculo (datos trimestrales)
30 sept. 2020 | 30 jun. 2020 | 31 mar. 2020 | 31 dic. 2019 | 30 sept. 2019 | 30 jun. 2019 | 31 mar. 2019 | 31 dic. 2018 | 30 sept. 2018 | 30 jun. 2018 | 31 mar. 2018 | 31 dic. 2017 | 30 sept. 2017 | 30 jun. 2017 | 31 mar. 2017 | 31 dic. 2016 | 30 sept. 2016 | 30 jun. 2016 | 31 mar. 2016 | 31 dic. 2015 | 30 sept. 2015 | 30 jun. 2015 | 31 mar. 2015 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Datos financieros seleccionados (US $ en millones) | ||||||||||||||||||||||||||||||
Ganancias (pérdidas) netas atribuibles a AbbVie Inc. | 2,308 | (738) | 3,010 | 2,801 | 1,884 | 741 | 2,456 | (1,826) | 2,747 | 1,983 | 2,783 | 52 | 1,631 | 1,915 | 1,711 | 1,391 | 1,598 | 1,610 | 1,354 | 1,517 | 1,239 | 1,366 | 1,022 | |||||||
Los activos totales | 149,621 | 149,530 | 91,199 | 89,115 | 59,441 | 57,142 | 56,769 | 59,352 | 66,164 | 61,641 | 69,342 | 70,786 | 68,840 | 66,994 | 65,664 | 66,099 | 66,626 | 67,211 | 53,720 | 53,050 | 54,832 | 53,855 | 26,699 | |||||||
Coeficiente de rentabilidad | ||||||||||||||||||||||||||||||
ROA1 | 4.93% | 4.65% | 9.25% | 8.84% | 5.48% | 7.21% | 9.44% | 9.58% | 11.43% | 10.46% | 9.20% | 7.50% | 9.66% | 9.87% | 9.61% | 9.01% | 9.12% | 8.51% | 10.19% | 9.70% | — | — | — | |||||||
Puntos de referencia | ||||||||||||||||||||||||||||||
ROA, competidores2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 4.90% | 4.52% | 5.36% | 5.43% | 4.80% | 4.23% | 3.88% | 3.53% | 1.24% | 1.35% | 0.67% | 0.63% | 2.91% | 1.65% | 2.12% | 2.66% | 3.47% | 5.72% | 6.17% | 10.72% | — | — | — | |||||||
Amgen Inc. | 11.37% | 11.23% | 12.45% | 13.13% | 13.55% | 13.40% | 12.62% | 12.64% | 3.27% | 3.49% | 3.12% | 2.48% | 10.18% | 10.27% | 10.14% | 9.95% | 9.71% | 9.85% | 9.61% | 9.69% | — | — | — | |||||||
Bristol-Myers Squibb Co. | -0.04% | -0.44% | 0.74% | 2.65% | 9.85% | 11.24% | 14.77% | 14.06% | 4.24% | 1.15% | 2.78% | 3.00% | 12.45% | 13.73% | 14.68% | 13.22% | 9.98% | 8.74% | 4.94% | 4.93% | — | — | — | |||||||
Eli Lilly & Co. | 12.68% | 13.39% | 13.46% | 21.17% | 20.97% | 20.28% | 16.46% | 7.36% | 1.01% | -0.34% | 2.53% | -0.45% | 5.17% | 5.98% | 5.81% | 7.05% | 6.50% | 6.76% | 6.68% | 6.77% | — | — | — | |||||||
Gilead Sciences Inc. | 2.08% | -0.46% | 8.31% | 8.74% | 4.55% | 9.42% | 9.38% | 8.57% | 2.47% | 3.38% | 5.30% | 6.58% | 17.94% | 20.27% | 21.90% | 23.70% | 26.63% | 32.71% | 36.30% | 34.93% | — | — | — | |||||||
Illumina Inc. | 8.62% | 9.56% | 12.97% | 13.70% | 13.73% | 13.45% | 11.52% | 11.87% | 10.12% | 11.08% | 10.23% | 13.81% | 15.49% | 15.39% | 16.10% | 10.81% | 10.49% | 10.86% | 10.93% | 12.52% | — | — | — | |||||||
Johnson & Johnson | 9.95% | 9.59% | 11.07% | 9.59% | 9.10% | 10.53% | 9.78% | 10.00% | 0.99% | 0.88% | 0.79% | 0.83% | 10.17% | 10.69% | 11.39% | 11.71% | 11.36% | 10.75% | 11.41% | 11.55% | — | — | — | |||||||
Merck & Co. Inc. | 12.83% | 11.56% | 11.95% | 11.66% | 11.18% | 11.15% | 10.20% | 7.53% | 3.93% | 1.58% | 1.84% | 2.72% | 3.11% | 5.48% | 4.50% | 4.11% | 5.58% | 5.32% | 4.67% | 4.36% | — | — | — | |||||||
Pfizer Inc. | 4.85% | 7.96% | 9.49% | 9.72% | 9.51% | 8.10% | 7.38% | 7.00% | 14.19% | 13.67% | 13.21% | 12.40% | 5.70% | 4.94% | 4.32% | 4.20% | 3.51% | 4.13% | 4.68% | 4.16% | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 19.62% | 20.68% | 14.46% | 14.29% | 15.38% | 15.71% | 18.88% | 20.83% | 16.64% | 15.99% | 15.23% | 13.67% | 14.69% | 14.24% | 12.32% | 12.84% | 11.68% | 11.97% | 12.56% | 11.34% | — | — | — | |||||||
Vertex Pharmaceuticals Inc. | 23.81% | 20.37% | 16.99% | 14.15% | 28.53% | 31.50% | 32.94% | 33.57% | 14.00% | 9.58% | 5.72% | 7.43% | 6.12% | 7.91% | 6.02% | -3.87% | -8.38% | -10.79% | -16.05% | -22.26% | — | — | — | |||||||
Zoetis Inc. | 12.12% | 12.37% | 13.97% | 12.99% | 12.96% | 12.52% | 12.75% | 13.25% | 11.13% | 12.96% | 11.25% | 10.06% | 10.09% | 11.25% | 11.18% | 10.73% | 8.93% | 8.50% | 5.07% | 4.28% | — | — | — |
Fuente: AbbVie Inc. (NYSE:ABBV) | Analysis of profitability ratios (Q) (www.stock-analysis-on.net)
1 Q3 2020 cálculo
ROA = 100
× (Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q3 2020
+ Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q2 2020
+ Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q1 2020
+ Ganancias (pérdidas) netas atribuibles a AbbVie Inc.Q4 2019)
÷ Los activos totales
= 100 × (2,308 + -738 + 3,010 + 2,801)
÷ 149,621 = 4.93%
2 Haga clic en el nombre del competidor para ver los cálculos.
Coeficiente de rentabilidad | Descripción | La compañia |
---|---|---|
ROA | Un índice de rentabilidad calculado como el ingreso neto dividido entre los activos totales. | El ROA de AbbVie Inc. se deterioró desde el primer trimestre de 2020 hasta el segundo trimestre de 2020, pero luego mejoró ligeramente desde el segundo trimestre de 2020 hasta el tercer trimestre de 2020. |